Telemammography for defeating breast cancer that connects to local health centers within 2 weeks.
UNDP Growth Stage Impact Ventures (GSIV) for SDGS, Certified B Corp (B Lab),
1 of every 8 women will develop breast cancer in their lifetime, and of the 700,000 lives it takes every year, 70% occur in developing countries. 80% of the population in developing countries does not have access to preventive diagnoses. Late diagnosis is a consequence of a lack of medical equipment, specialized doctors, awareness, and insufficient legislation that promotes annual screening exams. Digital penetration rates are still low in Latin America and other developing countries. Only 60% of doctors use electronic records and digital software.
Mamotest focuses on connecting with health centers throughout Latin America to give access to breast care to millions of women who have never gotten a mammogram before.
Mamotest targets every woman over 40 years of age. In Latin America, 80% of them do not have current access to mammograms, due to a lack for equipment, technicians, breast cancer radiologists and where they do, costs are prohibiting. Most of them do not have formal employment and depend on their partner's income, whose average salaries are around 500 USD, while trustable quality mammogram costs between 70 and 150 USD. The public sector sometimes serves these studies, but they have a 4 to 6 month waiting list. By connecting Mamotest centres in remote areas and collecting patient data we are able to subsidize the cost of mammograms for women, looking at reaching a prize as close to zero as possible and breaking down the biggest two barriers that separate women from early diagnosis: reach and cost. Additionally, A.I on our platform gathers data that helps connect cancer patients to doctors in their area and have full traceability on the health sector, allowing all information to be in hands of the patient and the wide array of professionals who treat them. With better data on women, governments will be able to make accurate budget decisions to treat the population. The cost of treating four women in stage 4 cancer with a 27% success rate can be used to treat 10 women in stage 1 cancer with 98% success rate. With Bolder in-house developed platform, we offer a free of charge personalized concierge attention through our Health Navigators, tracking, collecting and structuring the data of risk patient's evolution and experience at every stage of the journey, guaranteeing all oncologic patients their access to accessible, affordable and personalized treatment on time.
Expansion plans in the short term are aligned with Mamotest's expansion in Mexico via alliances with NGOs such as Pro Mujer, Fundacion Avon, MILC, private and public associations such as Instituto Mexicano de Seguro Social and Consorcio Mexicano de Hospitales, pathologic and oncologic institutions such as Digipath, COI.
